Compare Enveric Biosciences Inc (ENVB) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Illumina, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.37 (market cap $5.32M), while Illumina, Inc. trades at $191.47 (market cap $28.32B). The key difference: Illumina, Inc. is far larger — about 5323.3× Enveric Biosciences Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | ILMN | |
|---|---|---|
Market Cap | $5.32M | $28.32B |
Sector | Health | Health |
52-Week High | $17.40 | $194.33 |
52-Week Low | $1.28 | $91.00 |
Enterprise Value | $408.82K | $29.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
Illumina (ILMN) trades at $188.27, down 1.53% on the day, yet maintains a strong technical and fundamental posture. The stock is in a bullish trend, supported by consistent earnings beats, robust profitability margins, and positive analyst sentiment. Recent news highlights strong momentum in 2026, driven by sequencing demand and new product launches, positioning the company for growth despite competitive pressures.
The outlook for ILMN is positive, with earnings growth and market leadership in genomics offering upside potential. Key risks include intensifying competition from new entrants like Roche and execution challenges in a dynamic healthcare landscape. Investor sentiment remains buoyant, but vigilance on competitive threats and margin sustainability is warranted for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
